BRPI0909270A2 - Compostos de sirna para inibição de rtp801 - Google Patents

Compostos de sirna para inibição de rtp801

Info

Publication number
BRPI0909270A2
BRPI0909270A2 BRPI0909270-6A BRPI0909270A BRPI0909270A2 BR PI0909270 A2 BRPI0909270 A2 BR PI0909270A2 BR PI0909270 A BRPI0909270 A BR PI0909270A BR PI0909270 A2 BRPI0909270 A2 BR PI0909270A2
Authority
BR
Brazil
Prior art keywords
rtp801
inhibition
sirna compounds
sirna
compounds
Prior art date
Application number
BRPI0909270-6A
Other languages
English (en)
Inventor
Elena Feinstein
Rami Skaliter
Hagar Kalinski
Igor Mett
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Publication of BRPI0909270A2 publication Critical patent/BRPI0909270A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0909270-6A 2008-03-20 2009-03-17 Compostos de sirna para inibição de rtp801 BRPI0909270A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7018108P 2008-03-20 2008-03-20
PCT/IL2009/000302 WO2009116037A2 (en) 2008-03-20 2009-03-17 NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801

Publications (1)

Publication Number Publication Date
BRPI0909270A2 true BRPI0909270A2 (pt) 2015-08-11

Family

ID=41091311

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909270-6A BRPI0909270A2 (pt) 2008-03-20 2009-03-17 Compostos de sirna para inibição de rtp801

Country Status (11)

Country Link
US (1) US20110028531A1 (pt)
EP (1) EP2268316A4 (pt)
JP (1) JP2011517404A (pt)
KR (1) KR20100132531A (pt)
CN (1) CN102026670A (pt)
AU (1) AU2009227549A1 (pt)
BR (1) BRPI0909270A2 (pt)
CA (1) CA2718765A1 (pt)
MX (1) MX2010010303A (pt)
RU (1) RU2010138558A (pt)
WO (1) WO2009116037A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2577423C (en) 2004-08-16 2012-11-06 Quark Biotech, Inc. Therapeutic uses of inhibitors of rtp801
US7872119B2 (en) 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
CA2763537A1 (en) * 2009-06-08 2010-12-16 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
CA2815116A1 (en) 2010-10-27 2012-05-03 Devgen Nv Down-regulating gene expression in insect pests
AU2011338682B2 (en) * 2010-12-06 2017-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising threose modifications
CN103917647B (zh) 2011-11-03 2020-07-10 夸克制药公司 用于神经保护的方法和组合物
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2014043289A2 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
EP3568482A4 (en) 2017-01-10 2020-12-16 Arrowhead Pharmaceuticals, Inc. ALPHA-1 ANTITRYPSIN (AAT) RNA INTERFERENCE (RNA) AGENTS, COMPOSITIONS CONTAINING THEM, AND PROCEDURES FOR USE THEREOF

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235886B1 (en) * 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
EP0748382B1 (en) * 1993-09-02 2002-11-06 Ribozyme Pharmaceuticals, Inc. Non-nucleotide containing enzymatic nucleic acid
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6251666B1 (en) * 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6091048A (en) * 1997-05-16 2000-07-18 Illinois Tool Works Inc. Welding machine with automatic parameter setting
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
ES2234563T5 (es) * 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
CA2386270A1 (en) * 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
EP2345742B1 (en) * 2000-03-30 2014-06-11 The Whitehead Institute for Biomedical Research RNA sequence-specific mediators of RNA interference
US6693187B1 (en) * 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
ES2728168T3 (es) * 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
US20070032441A1 (en) * 2001-05-18 2007-02-08 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
ES2346640T4 (es) * 2001-10-26 2011-04-26 Noxxon Pharma Ag Ácido l-nucleico modificado.
MXPA05001355A (es) * 2002-08-05 2005-09-30 Atugen Ag Formas nuevas adicionales de moleculas de arn de interferencia.
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
EP1620544B1 (en) * 2003-04-17 2018-09-19 Alnylam Pharmaceuticals Inc. MODIFIED iRNA AGENTS
PL1633767T3 (pl) * 2003-06-02 2019-07-31 University Of Massachusetts Sposoby i kompozycje do kontrolowania wydajności wyciszania rna
WO2005001043A2 (en) * 2003-06-02 2005-01-06 University Of Massachusetts METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
JP2008501693A (ja) * 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク． 遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
AU2005272816B2 (en) * 2004-08-10 2011-08-11 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
CA2577423C (en) * 2004-08-16 2012-11-06 Quark Biotech, Inc. Therapeutic uses of inhibitors of rtp801
NL2000439C2 (nl) * 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
CN101484588B (zh) * 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US7872119B2 (en) * 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
US20100292301A1 (en) * 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
CN101815521B (zh) * 2007-10-03 2014-12-10 夸克制药公司 新siRNA结构

Also Published As

Publication number Publication date
EP2268316A2 (en) 2011-01-05
WO2009116037A3 (en) 2010-03-11
KR20100132531A (ko) 2010-12-17
CN102026670A (zh) 2011-04-20
JP2011517404A (ja) 2011-06-09
AU2009227549A1 (en) 2009-09-24
MX2010010303A (es) 2010-10-20
CA2718765A1 (en) 2009-09-24
RU2010138558A (ru) 2012-03-27
EP2268316A4 (en) 2011-05-25
US20110028531A1 (en) 2011-02-03
WO2009116037A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
BRPI0909270A2 (pt) Compostos de sirna para inibição de rtp801
LTPA2019009I1 (lt) C7-fluoru pakeisti tetraciklino junginiai
SMT201600267B (it) Inibitori di syk imidazopirazinici
SMT201600008B (it) Composti di piridazinone
DK2346888T3 (da) Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
BRPI0923433A2 (pt) Síntese de compostos fucosilados
DK3289876T3 (da) Forbindelser til behandling af cancer
DK3354650T3 (da) Forbindelser der er nyttige som inhibitorer af ATR-kinase
DK2414362T3 (da) Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
BRPI0816258A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BRPI0922880A2 (pt) compostos inibidores de quinase
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
BRPI1015274A2 (pt) instalação para o tratamento de superfície de peças
BRPI0920621A2 (pt) processos para síntese de composto macrolidos
BRPI0912475A2 (pt) compostos como inibidores de quinase
BRPI0820677A2 (pt) Misturas de compostos pesticidas
SMT201600031B (it) Composti eterociclici di fenossimetile
UY33156A (es) Nuevos compuestos tienopirrol
BRPI0813788A2 (pt) Processo para preparação de metacrilato de alila
BRPI0920728A2 (pt) Composição estabilizada para tratamento de psoríase
BRPI0821567A2 (pt) Misturas de compostos pesticidas
BRPI0820650A2 (pt) Misturas de compostos pesticidas

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.